Clinical trials: HIV 2 Infection
HIV Infections
TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278
The purpose of this study is to examine the safety, local tolerability and pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of a…
- Trial name
- NCT01031589
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers
The purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers.
- Trial name
- EV03/ANRSVAC20 (NCT00490074)
- Testing
- DNA-C, NYVAC-C
- Where
- 2 sites in France, Switzerland
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Infant Morbidity
Mitigating Infectious Morbidity and Growth Deficits in HIV Exposed Uninfected infanTs With Human Milk Oligosaccharides
Primary Objective: To evaluate the effects of synbiotics on infectious morbidity and growth while it is in place from 4 to 24 weeks of age.
- Conditions
- HIV, Infant Morbidity, Breast Feeding
- Trial name
- MIGH-T MO (NCT05282485)
- Testing
- Synbiotic, Maltodextrin
- Where
- South Africa
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hiv
Pharmacokinetics and Safety of DolutegravIr in Neonate
A Phase I/II, open-label, single arm, two-stage trial to evaluate the single and multi-dose PK and safety of DTG in HIV-exposed neonates on ARV prophylaxis.
- Trial name
- PETITE-DTG (NCT05590325)
- Testing
- Dolutegravir
- Where
- South Africa
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Desmond Tutu TB Centre
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Human Immunodeficiency Virus (HIV) Infections
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for…
- Trial name
- NCT05130086
- Testing
- Islatravir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
This observational study will prospectively characterize the long-term symptoms and side effects of COVID-19 in cohorts of people living with and without HIV.
- Trial name
- NCT04958889
- Testing
- No intervention
- Where
- United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.
- Trial name
- NCT00071851
- Testing
- VRC-HIVDNA009-00-VP
- Where
- 14 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Intravaginal rings (IVRs) may offer an ideal way to deliver antiretroviral (ARV) drugs to prevent HIV infection. This study will evaluate the pharmacokinetics and safety of two IVRs containing different doses of a combination of…
- Trial name
- NCT02419456
- Testing
- MK-2048A IVR (Low Dose), MK-2048A IVR (Original Dose)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, STI
Appalachian Partnership to Reduce Disparities (Aim 2)
By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically…
- Conditions
- HIV/AIDS, STI, HCV
- Trial name
- NCT04378439
- Testing
- Peer Navigation, mHealth
- Where
- United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
HIV Infections
Pharmacokinetics of Lamivudine at Two Different Doses
The purpose of the study is to measure the pharmacokinetics (how a drug is absorbed, distributed and eliminated from the body) of lamivudine (3TC) and its active component after 3TC is given at two different doses, 300mg and…
- Trial name
- ENCORE2 (NCT00985647)
- Testing
- Lamivudine (3TC)
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV Infections, HIV Seronegativity
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
AMENDED 8/94: To expand the safety and immunogenicity profile of MN rgp160 vaccine (Immuno-AG) by administering a higher dose (800 mcg) at 0, 1, 6, and 12 months and 0, 2, 8 and 14 months (these two schedules were compared in VEU…
- Trial name
- NCT00001043
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
The purpose of this study is to evaluate the safety of and immune response to two HIV vaccine formulations, rMVA-HIV and rFPV-HIV, alone and in combination, in HIV uninfected adults.
- Trial name
- NCT00083603
- Testing
- rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV
- Where
- 6 sites in United States, Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CIN 2/3, HIV Infections
5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa
This is a single arm study on the safety, feasibility, and acceptability of adjuvant, self-administered, intravaginal 5-Fluorouracil (5-FU) following treatment for high-grade cervical precancer (CIN2/3) among women living with…
- Trial name
- NCT05362955
- Testing
- Intravaginal 5-Fluorouracil (5-FU)
- Where
- Kenya
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
HIV Testing, HIV Infections
Near Patient Study of the OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in Oral Fluid and Fingerstick Whole Blood
Point-of-care (POC) tests for HIV are easy to use, rapid and provide accurate results while the patient is still in-front of a healthcare provider (HCP).
- Trial name
- NCT04810559
- Testing
- OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test
- Where
- 4 sites in Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
HIV Infection, Infection, Human Immunodeficiency Virus
Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
To evaluate the single dose relative bioavailability of GSK1265744 10mg administered in either oral solution fasted, two 5mg tablets fasted, or two 5mg tablets following a moderate meal.
- Trial name
- NCT00812318
- Testing
- GSK1265744 10 mg oral solution, GSK1265744 5 mg tablet
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus, Contraception
Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV
It is important to make sure that women have access to effective methods of contraception to prevent pregnancy so that they can make choices about when and if they will have their first or next child.
- Conditions
- Human Immunodeficiency Virus, Contraception, ART
- Trial name
- CODA (NCT04910711)
- Testing
- Dolutegravir, Levonorgestrel implant, Depo medroxyprogesterone acetate injection
- Where
- Botswana
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Botswana Harvard AIDS Institute Partnership
HIV Infections
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
The purpose of this study is to evaluate the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with an experimental modified vaccinia HIV vaccine (MVA) in HIV uninfected adults.
- Trial name
- NCT00574600
- Testing
- SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine
- Where
- 4 sites in United States, South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R)…
- Trial name
- NCT02583464
- Testing
- Tenofovir disoproxil fumarate and emtricitabine
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
HIV Infections
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
- Trial name
- CABNATE (NCT07275606)
- Testing
- Oral CAB, IM CAB LA
- Where
- South Africa
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare